Neoadjuvant Biweekly Treatment Followed by Weekly Treatment of Breast Cancer
Status:
Completed
Trial end date:
2012-07-01
Target enrollment:
Participant gender:
Summary
We proposed to use 4 cycles of AC q 2 weeks, as used in the dose dense adjuvant study with
GM-CSF support on days 3-9 of the cycle. After the completion of AC we plan to administer
paclitaxel and carboplatin weekly for a total of 12 doses with one week rest after every 3
weeks of treatment over 12 weeks. Patients who are her-2 over-expressors by FISH
(fluorescence in situ hybridization) will also receive Trastuzumab with weekly carboplatin
and paclitaxel as the combination TC±H has been found to be synergistic in advanced breast
cancer with improved clinical outcome.
Phase:
Phase 2
Details
Lead Sponsor:
Rita Sanghvi, Mehta University of California, Irvine